Chronic Kidney Disease and Mesenchymal stem/stromal cells (MSC): what the trial registry contains

Why this is studied in Chronic Kidney Disease

Chronic kidney disease is progressive nephron loss with fibrosis and inflammation. Cell approaches aim to slow decline rather than regenerate nephrons, and the kidney's limited regenerative capacity makes restoration claims implausible. Registered work sits close to nephrology practice, which means endpoints are unusually well defined compared with softer indications.

What MSC means in this table

Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.

The numbers

Every figure below comes from one reproducible query (chronic kidney disease x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Evidence here is mid-maturity: a handful of Phase 3 or 4 registrations (1 of 23) sit above a much larger early-phase base.

Of those, 8 are marked completed and 2 were terminated, withdrawn or suspended — a stop rate of 9%, worth weighing when a clinic quotes 'ongoing research' as reassurance.

Median planned enrolment is 30 participants (largest single study: 130). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

6 countries host at least one site. United States is the largest single contributor at roughly 55% of country mentions in this sample.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

The sponsor mix is commercial (5 academic or hospital, 9 commercial among the most frequent lead sponsors).

• Mayo Clinic — 7 records
• LaTonya J. Hickson — 2 records
• Royan Institute — 2 records
• The Affiliated Hospital of Xuzhou Medical University — 1 record
• The Foundation for Orthopaedics and Regenerative Medicine — 1 record
• The First Affiliated Hospital with Nanjing Medical University — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

Treat this as a map of research activity. It tells you whether a claim has an evidence programme behind it — not whether the treatment helped anyone.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many MSC studies for Chronic Kidney Disease are recruiting right now?

5 of 23 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is MSC an approved treatment for Chronic Kidney Disease?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 23 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on MSC for Chronic Kidney Disease?

1 of 23 records carry a Phase 3 or Phase 4 label and 8 are marked completed. Registrations run from 2007 to 2026.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.